SCHEMBL834080

SCHEMBL834080

N#Cc1cccc2c1C(=O)N(c1ccc(CN3CCCC3)cc1)C2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.65
HTR2C P28335 5/20 0.47
HTR2A P28223 2/20 0.42
HTR2B P41595 2/20 0.42
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
CHKA P35790 1/20 0.39
ALDH1A1 P00352 1/20 0.38
ACHE P22303 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ESR1 P03372 1/20 0.37
POLB P06746 1/20 0.37
NR4A1 P22736 1/20 0.37
APEX1 P27695 1/20 0.37
PTPN7 P35236 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835113 0.88 PARP1 (0.67) PARP1HTR2CHTR2AHTR2BCYP2D6
SCHEMBL835994 0.83 PARP1 (0.49) PARP1HTR2CHTR2AHTR2BALDH1A1
SCHEMBL835746 0.79 PARP1 (1.00) PARP1
SCHEMBL834523 0.77 PARP1 (0.61) PARP1HTR2CHTR2AHTR2BKDM4E
SCHEMBL834078 0.77 PARP1 (0.63) PARP1HTR2CHTR2AHTR2BTSHR
SCHEMBL10113636 0.72 TP53 (0.62) PARP1HTR2CCYP2D6CYP2C19KDM4E
SCHEMBL2022596 0.72 PARP1 (0.59) PARP1HTR2CHTR2AHTR2BTSHR
SCHEMBL1860022 0.69 PARP1 (0.80) PARP1
SCHEMBL1863422 0.68 PARP1 (0.79) PARP1
SCHEMBL833220 0.68 PARP1 (1.00) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143284-B2 2-cyclohexyl-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide; allergic encephalitis, arthritis, cardiac and kidney toxicities from doxorubicin-based and platinum-based antineoplastic agents, carcinoma of the breast, central nervous system inflammation, cervical carcinoma, ABBOTT LABORATORIES (US) 2012-03-27 US disclosed
US-20080108659-A1 POLY(ADP-RIBOSE)POLYMERASE INHIBITORS ABBVIE INC. 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108659-A1 POLY(ADP-RIBOSE)POLYMERASE INHIBITORS PARP1, PARP11, PARP2 PARP1 1/4885HTR2C 4265/4885HTR2A 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.